Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up
Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up
$200.00
Shortly after US FDA approval of its blood-disorder drug Cablivi, Sanofi announced “a rigorous pipeline prioritization review.” It’s fast-tracking 17 programs and discontinuing 13 development and 25 research projects. What’s left? Will Sanofi divest its animal health and/or consumer healthcare units? Find out what experts are saying.
Author: Kevin Grogan
Publisher: Scrip
- Description
Overview
Sanofi has re-focused on cancer and rare diseases. Immediately after Sanofi received US FDA approval for its blood disorder drug Cablivi (caplacizumab), the company announced “a rigorous pipeline prioritization review.” As a result of this overhaul Sanofi is fast-tracking 17 programs. At the same time, it is discontinuing 13 development and 25 research projects. What’s left? Find out just how many projects are in Sanofi’s R&D pipeline at this point. What does Sanofi’s enthusiasm for the rare-diseases space and its newly-formed rare blood disorder franchise mean going forward? Will Sanofi divest its animal health and/or consumer healthcare units? Find out what experts are saying.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the